Celldex appoints Rita Jain, M.D. to Board of Directors

Celldex Therapeutics, Inc.

Rita Jain, M.D. appointed to Celldex Board effective February 16, 2023.
Dr. Jain receives initial option grant for 17,100 shares vesting over three years.
She previously served as CMO of ChemoCentryx and Immunovant, and SVP/CMO at Akebia.
Dr. Jain currently serves on boards of Provention Bio and AM Pharma supervisory board.
Appointment fills board vacancy; no family relationships or material transactions disclosed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rita Jain, M.D.

member of the Board of Directors

CLDX · Celldex Therapeutics, Inc.

Effective: 2023-02-16
Filed: February 21, 2023, 6:59 PM ET

Rita Jain, M.D. was appointed as a member of our Board of Directors (the “ Board ”) on February 16, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Rita Jain, M.D. was appointed as member of the Board of Directors at Celldex Therapeutics, Inc..

Action: appointed
Role: member of the Board of Directors

Exact text from the filing

Rita Jain, M.D. was appointed as a member of our Board of Directors (the “ Board ”) on February 16, 2023.

View on SEC.gov

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-023768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.